Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Nasr

Showing results (101-110 of 112) with videos related to

Pageof 12
Sort By:
European Urology|February 27, 2025
Effects of Enzalutamide on the Sexual Activity of Patients with Biochemically Recurrent Prostate Cancer: A Post Hoc Analysis of Patient-reported Outcomes in the EMBARK StudyStephen J Freedland, John P Mulhall, Martin Gleave, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 11, 2024
Dose-Dense Mini-Hyper-CVD, Inotuzumab Ozogamicin and Blinatumomab Achieves Rapid MRD-Negativity in Philadelphia Chromosome-Negative B-cell Acute Lymphoblastic LeukemiaNicholas J Short, Elias Jabbour, Trevor Jamison, et al.
Cancers|May 11, 2024
High-Grade Pleomorphic Sarcomas Treated with Immune Checkpoint Blockade: The MD Anderson Cancer Center ExperienceLewis F Nasr, Marianne Zoghbi, Rossana Lazcano, et al.
Frontiers in Oncology|September 26, 2024
Outcomes and toxicities in patients with diffuse-large B cell lymphoma involving the gastrointestinal tract and digestive organsGohar S Manzar, Elaine E Cha, Kelsey L Corrigan, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 21, 2024
Outcome of Patients With Central Nervous System Multiple Myeloma (CNS-MM) Treated With CNS-Directed Radiation TherapyGohar S Manzar, Stephanie O Dudzinski, Alison K Yoder, et al.
Blood|March 29, 2024
Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALLYaqi Zhao, Nicholas J Short, Hagop M Kantarjian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 26, 2024
Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory <i>FLT3</i>-Mutated AMLNicholas J Short, Naval Daver, Courtney D Dinardo, et al.
Medrxiv : the Preprint Server for Health Sciences|December 18, 2023
Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALLYaqi Zhao, Nicholas J Short, Hagop M Kantarjian, et al.
International Journal of Radiation Oncology, Biology, Physics|September 20, 2024
Characterization of Lymphopenia and Correlating the Risk of Cytopenias With Dose and Bone Marrow Volume Irradiated in Aggressive B Cell Lymphoma Patients Bridged With Radiation Therapy for Chimeric Antigen Receptor-T Cell TherapyGohar S Manzar, Susan Y Wu, Stephanie O Dudzinski, et al.
Frontiers in Immunology|February 17, 2025
Outcomes with bridging radiation therapy prior to chimeric antigen receptor T-cell therapy in patients with aggressive large B-cell lymphomasGohar S Manzar, Chelsea C Pinnix, Stephanie O Dudzinski, et al.
Pageof 12

Showing results (101-110 of 112) with videos related to

Sort By:
Pageof 12
European Urology|February 27, 2025
Effects of Enzalutamide on the Sexual Activity of Patients with Biochemically Recurrent Prostate Cancer: A Post Hoc Analysis of Patient-reported Outcomes in the EMBARK StudyStephen J Freedland, John P Mulhall, Martin Gleave, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 11, 2024
Dose-Dense Mini-Hyper-CVD, Inotuzumab Ozogamicin and Blinatumomab Achieves Rapid MRD-Negativity in Philadelphia Chromosome-Negative B-cell Acute Lymphoblastic LeukemiaNicholas J Short, Elias Jabbour, Trevor Jamison, et al.
Cancers|May 11, 2024
High-Grade Pleomorphic Sarcomas Treated with Immune Checkpoint Blockade: The MD Anderson Cancer Center ExperienceLewis F Nasr, Marianne Zoghbi, Rossana Lazcano, et al.
Frontiers in Oncology|September 26, 2024
Outcomes and toxicities in patients with diffuse-large B cell lymphoma involving the gastrointestinal tract and digestive organsGohar S Manzar, Elaine E Cha, Kelsey L Corrigan, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 21, 2024
Outcome of Patients With Central Nervous System Multiple Myeloma (CNS-MM) Treated With CNS-Directed Radiation TherapyGohar S Manzar, Stephanie O Dudzinski, Alison K Yoder, et al.
Blood|March 29, 2024
Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALLYaqi Zhao, Nicholas J Short, Hagop M Kantarjian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 26, 2024
Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory <i>FLT3</i>-Mutated AMLNicholas J Short, Naval Daver, Courtney D Dinardo, et al.
Medrxiv : the Preprint Server for Health Sciences|December 18, 2023
Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALLYaqi Zhao, Nicholas J Short, Hagop M Kantarjian, et al.
International Journal of Radiation Oncology, Biology, Physics|September 20, 2024
Characterization of Lymphopenia and Correlating the Risk of Cytopenias With Dose and Bone Marrow Volume Irradiated in Aggressive B Cell Lymphoma Patients Bridged With Radiation Therapy for Chimeric Antigen Receptor-T Cell TherapyGohar S Manzar, Susan Y Wu, Stephanie O Dudzinski, et al.
Frontiers in Immunology|February 17, 2025
Outcomes with bridging radiation therapy prior to chimeric antigen receptor T-cell therapy in patients with aggressive large B-cell lymphomasGohar S Manzar, Chelsea C Pinnix, Stephanie O Dudzinski, et al.
Pageof 12